BusinessPeregrine to Report Financial Results for Second Quarter of Fiscal Year 2017 After Market Close on December 12, 2016By Nasdaq OMXDec 5, 2016, 9:05 PM UTC
BusinessImmune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and Neo-Antigens) and G100 For Intratumoral ImmunotherapyBy Nasdaq OMXDec 5, 2016, 1:01 PM UTC
BusinessImmune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and Neo-Antigens) and G100 For Intratumoral ImmunotherapyBy Nasdaq OMXDec 5, 2016, 1:01 PM UTC
BusinessSurefire Medical Receives Grant to Pursue Phase 1b Clinical Trial of CAR-T Immunotherapy Delivery through Precision Infusion SystemBy Nasdaq OMXNov 15, 2016, 11:00 AM UTC
BusinessNew Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting Antibodies in a Preclinical Melanoma ModelBy Nasdaq OMXNov 14, 2016, 1:05 PM UTC
BusinessNew Immune Design Data Highlights Expanded Product Potential of ZVex® Platform at the 2016 SITC Annual MeetingBy Nasdaq OMXNov 11, 2016, 1:00 PM UTC
BusinessPreclinical Research Demonstrates Peregrine Pharmaceuticals’ PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXOct 24, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXOct 10, 2016, 12:05 PM UTC
